Stephen G. Madison, Bscpharm, Rph, Mba

Stephen G. Madison, Bscpharm, Rph, Mba Email and Phone Number

President and CEO @ Las Vegas, NV, US
Las Vegas, NV, US
Stephen G. Madison, Bscpharm, Rph, Mba's Location
Las Vegas, Nevada, United States, United States
Stephen G. Madison, Bscpharm, Rph, Mba's Contact Details

Stephen G. Madison, Bscpharm, Rph, Mba work email

Stephen G. Madison, Bscpharm, Rph, Mba personal email

n/a

Stephen G. Madison, Bscpharm, Rph, Mba phone numbers

About Stephen G. Madison, Bscpharm, Rph, Mba

After a 2-year retirement I am returning to the work force. I am seeking full-time employment with a major oncology/hematology company. I am seeking either a Vice President or a Global Executive Director level Marketing, Sales or Business Development position where I can apply my wide range of highly successful oncology/hematology business experience & skills, including strong working relationships with US & global key opinion leaders (KOLs) I have no interest whatsoever in being a President. I have already held that position with my own companies. My goal is to use my experience to help a major pharmaceutical company build their cancer business.For most of my career, I have traveled extensively in the US and abroad. I was an Oncology Product Manager for Bristol Myers Squibb (BMS) in the US and global markets. I have also lived and worked in Mexico City as a Sr. Director reporting to the BMS President of Latin America and helping the BMS Latin American country managers implement the BMS Latin American President's strategic and tactical oncology/hematology programs. I started my career working for Eli Lilly in sales. I was promoted into marketing and recruited to work for Bristol-Myers. Squibb. I started an oncology Advertising Agency. BMS hired me and my focus was on major markets in Asia and Europe where I traveled approximately 40% of the time.I was also founder, President & CEO of an oncology/hematology CME/CE company. I developed oncology/hematology CME/CE programs working closely with numerous academic key opinion leaders in the US and globally. Approximately 50% of my work was in the US and 50% was ex-US, with a focus on the major European countries, and the major Asian countries such as Japan, Korea, Thailand, and China. I was also founder, President & CEO of an oncology/hematology full-service advertising agency for Bristol-Myers Squibb, Lilly Oncology, and Genentech.Because I have worked full time solely from my home office for many years, I am able to work remotely, if needed. I am highly productive working remotely from my home office, and willing and able to travel anywhere globally as needed. I am happily married to a wonderful and supportive wife who was born and raised in Thailand and is a naturalized US citizen. We have no children and are totally flexible to travel anywhere as needed. I will be an asset to any major pharmaceutical company who seeks to leverage my successful experiences globally. I have an excellent reputation and numerous excellent references. I look forward to the opportunity to interview with you. Thank you.

Stephen G. Madison, Bscpharm, Rph, Mba's Current Company Details
Steve Madison Cancer Consulting

Steve Madison Cancer Consulting

President and CEO
Las Vegas, NV, US
Stephen G. Madison, Bscpharm, Rph, Mba Work Experience Details
  • Steve Madison Cancer Consulting
    President And Ceo
    Steve Madison Cancer Consulting
    Las Vegas, Nv, Us
  • Steve Madison Cancer Consulting
    President & Ceo
    Steve Madison Cancer Consulting Oct 2023 - Present
    Las Vegas, Nv
    Senior oncology/hematology strategic business development, marketing, and clinical consultant to the pharmaceutical and diagnostics industries specializing in new and emerging oncology/hematology products.In 2023 after closing my CME company I restarted Steve Madison Cancer Consulting. I conduct customized one-on-one KOL interviews in all malignancies. My expertise includes the most current and sophisticated investigational immunologic agents and novel therapeutics in clinical development. My ability to conduct these KOL interviews is second to none. Arguably, nobody has the anywhere near the number of working KOL relationships in oncology/hematology worldwide than I do. My in-depth knowledge of investigational and newly-approved drugs also results from my ongoing monitoring of the oncology/hematology literature and other data sources to identify unmet medical needs in all malignancies for my CME company. I’m also an emeritus ASCO member. As a result, I have an understanding of a very large number of emerging & marketed anti-cancer agents. The main uses of the information obtained from my interviews are: 1) Provide pharmaceutical executives in clinical development, or pre-launch/post-launch marketing, detailed opinions on a product and its competition that KOLs rarely can provide in advisory boards and traditional marketing research. 2) Provide vital information that is essential for validating or fine-tuning clinical development programs & marketing strategies. 3) The information is also very useful to help evaluate potential in-licensing candidates & companies. I initially began conducting my one-on-one KOL interview consulting while working at several pharmaceutical companies, beginning in 1985 while working in oncology as Sr. Oncology Product Manager at Bristol Myers Squibb, and while operating my several continuing education companies for nearly 20 years that focused on late-stage and newly approved investigational oncology/hematology agents.
  • Oncology Learning Center Aka And Dba Biomedical Learning Institute
    President & Ceo
    Oncology Learning Center Aka And Dba Biomedical Learning Institute Mar 2007 - Oct 2023
    Plano,Tx
    This was my second Continuing Education Company. It held the following three accreditations. -ACCME-accredited provider of continuing education to physicians with the special "Accreditation with Commendation" status, a six-year term, awarded to only 10 to 15% of accredited providers with exceptional CME programs that included additional, non-required core CME criteria, such as those evaluating patient outcomes.-ACPE-accredited provider of continuing education to pharmacists with a special, six-year term.-ANCC-accredited provider of continuing education to nurses with "Accreditation with Distinction" status.Additional highlights are contained in my resume
  • Oncology Learning Center Dba Aka Biomedical Learning Institute
    Chief Executive Officer
    Oncology Learning Center Dba Aka Biomedical Learning Institute Mar 2007 - Oct 2023
    Plano, Tx
  • Biomedical Learning Institute (Bmli)
    President & Ceo
    Biomedical Learning Institute (Bmli) 2007 - 2022
    Dallas/Fort Worth Area
    I started and managed this company. ACCME-accredited provider of continuing education to physicians with the special "Accreditation with Commendation" status, a six-year term, awarded to only 10 to 15% of accredited providers with exceptional CME programs that included additional, non-required core CME criteria, such as those evaluating patient outcomes.ACPE-accredited provider of continuing education to pharmacists with a special, six-year term.ANCC-accredited provider of continuing education to nurses with "Accreditation with Distinction" status.I personally wrote hundreds of highly scientific, oncology and hematology clinical CME/CE grant proposals for physicians, nurses and pharmacists. These were funded by pharmaceutical companies for their products pending FDA or EMA approval. Receiving grant funding was highly competitive, but we were among the most successful of all CME/CE providers. For the first two years I hired a medical/scientific writer who wrote our company's grant proposals based upon the unmet medical needs concepts that I identified. She was a prior client of my company, S.G.Madison, who worked at Celgene and Berlex. After she joined Genentech, I wrote all of our proposals doing my own research and with help from KOLs. We averaged two ASCO satellite symposia annually, and numerous satellite symposia at other annual major cancer meetings such as ESMO, ASH, ONS, ASHP, and special ASCO meetings such as ASCO GU, ASCO GI, ASCO Breast.I also conceived the ideas for unmet medical needs with oncology and hematology drugs, and I planned and wrote all grant proposals that secured funding for BMLI's own major oncology/hematology medical education programs including our highly successful series of the Targeted Therapies Symposia for the major malignancies, and, our highly successful Master Classes I designed and conducted exclusively for pharmaceutical industry executives who attended from most oncology and hematology companies. KOLs were the faculty.
  • Oncology Learning Center, Inc.
    President And Ceo
    Oncology Learning Center, Inc. 2007 - 2022
    Dallas/Fort Worth Area
    I also started and managed this company. It operated with the accreditations granted to BMLI.Both the BioMedical Learning Institute (BMLI) and the Oncology Learning Center conceived the unmet medical needs, and planned, developed and conducted accredited continuing, professional, cancer education activities for physicians, nurses, Nurse Practitioners, pharmacists and other cancer HealthCare professionals. Among the greatest achievements of the Oncology Learning Center were the following:In a highly competitive contest, Bristol Myers Squibb awarded us their coveted ASCO satellite symposium in 2010 that essentially "launched" the monoclonal antibody, ipilimumab, as the first drug to improve overall survival in malignant melanoma after nearly 20 years of treating this cancer with only chemotherapy. The symposium was held in the Hyatt Hotel attached to the ASCO McCormack Place Convention Center, and the room was packed to capacity with 500+ attendees. Other major and highly notable and successful symposia we conducted globally included the annual Fox Chase Cancer Center Symposium in Hawaii; The annual Translational Research for Breast Cancer Symposium co-chaired by Drs. Slamon and Crown in Dublin Ireland that our company conceived and conducted; The annual French National Breast Cancer Symposium co-chaired by Drs. Khayat and Hortobagyi in Paris; The annual Anti-Angiogenesis Symposium that my company conceived and conducted in Dallas,TX and later in Tucson, AZ.And perhaps our final crowning achievement was being awarded funding by several pharmaceutical companies for two of the only four ASCO satellite symposia in 2021 when COVID-19 caused ASCO to be a virtual meeting. My company was prepared for conducting our two symposia virtually, and they were extremely successful with between nearly 500 and 900 virtual participants worldwide. These were both on non-small cell lung cancer. One was chaired by Dr. Scagliotti and the other was chaired by Dr. Camidge.
  • Customized Pharmaceutical Learning Systems, Inc. (Cpls), Cancer Comm And Kol Access
    President & Ceo
    Customized Pharmaceutical Learning Systems, Inc. (Cpls), Cancer Comm And Kol Access 2002 - 2007
    Dallas/Fort Worth Area
    During the 5-year period of my non-compete agreement after I sold S.G. Madison & Associates,Inc., I formed a new corporation, Customized Pharmaceutical Learning Systems, Inc.(CPLS), focusing on two main areas that did not violate my non-compete agreement from the sale of my prior companies: marketing research, and training for oncology/hematology executives in sales and also in the home office. Within CPLS, I formed three companies: 1) CPLS itself where I did most of the medical and scientific research, and medical/scientific writing where we developed Web-based and in-person training for in-house executives (such as in marketing, medical and clinical development and, for field based sales and sales management that were new or relatively new to oncology/hematology; 2) Cancer Comm that conducted marketing research with oncologists, hematologists and cancer nurses and pharmacists; and 3) KOL Access where I personally conducted one-on-one academic KOL interviews. Some of my major clients were Amgen to help them with all of the in-person regional training meetings, and a comprehensive Web-based program for the pre-launch training for panitumumab; Novartis where I was awarded a contract to develop a highly successful global “Oncology 101” web-based training program; and numerous other companies such as ImClone Systems, Sanofi Oncology, Bayer, Genentech, Berlex Oncology, Poniard and a few others.For several companies I again conducted dozens of one-on-one KOL interviews to provide them with in-depth, detailed information helping them with pre- and post-launch strategies, tactics and, modifications to late-stage clinical trials. One major and highly successful program was that I interviewed 30 European KOLs (one-on-ones each for one hour) during the entire annual ESMO meeting in Barcelona for Berlex Pharmaceuticals. The objective of the ESMO interviews was to provide advice to Berlex R&D to redesign its pivotal trial for an investigation agent for colorectal cancer.
  • The Center For Biomedical Continuing Education (Cbce)
    Founder And Owner, President & Ceo
    The Center For Biomedical Continuing Education (Cbce) 1997 - 2002
    Dallas/Fort Worth Area
    ACCME-accredited provider of continuing education to medical oncologists and hematologists.ACPE-accredited provider of continuing education to oncology/hematology pharmacists.ANCC-accredited provider of continuing education to oncology/hematology nurses.This was a company that was very similar in scope and mission to the subsequent CME and CE company that I started a few years later in 2007, the BMLI.After receiving our three accreditations, I hired two medical scientific writers: a PhD who had worked for MD Anderson Cancer Center, who left MD Anderson Cancer Center to work as an independent contractor, and a pediatric oncologist who left clinical practice to also work as an independent contractor. With my targeting the specific companies and malignancies and my general direction, they wrote more than 200 detailed and scientifically and clinically referenced CME and CE grant proposals and grants, primarily oncology/hematology educational programs, for physicians, nurses and pharmacists, typically for products of pharmaceutical companies with less than one year before they received FDA and EMA approval. While working for Bristol Myers Squibb the CBCE also wrote, developed and conducted CME and CE grants and proposals for the BMS HIV protease inhibitors in the US, and Megace for weight gain; and we also developed and conducted non-accredited symposia for protease inhibitors and Megace in most major European countries.In addition to our work for BMS and Lilly Oncology, we developed dozens of highly successful CME/CE programs that we owned such as the highly successful annual Targeted Therapies of Lung Cancer, Breast Cancer, G/U cancers, G/I Cancers Symposia in the US and several European cities, and numerous other multi-company supported symposia such as the annual Angiogenesis symposium in Dallas and Arizona, the Translational Breast Cancer Research Symposium in Dublin Ireland and Los Angeles, We also did the annual Fox Chase Cancer Center Symposium.
  • S.G. Madison & Associates, Inc.
    Founder And Owner, President & Ceo
    S.G. Madison & Associates, Inc. 1994 - 2002
    Dallas/Fort Worth Area
    I started S.G. Madison & Associates, Inc., with all of the money I had. I selected Irving, TX as its headquarters because it was near the DFW airport. I remained in the area because I anticipated travel from Dallas to potential pharmaceutical companies clients in California, New Jersey and New York as I built my business with Lilly Global oncology, Bristol Myers Squibb (BMS) Global and subsequently BMS US Oncology and HIV. My business plan was to build and operate an advertising, medical education, marketing, promotion, and consulting company specializing in oncology and hematology.My company was the Advertising Agency of record on an annual retainer basis for Lilly Oncology, Bristol Myers Squibb (BMS) US and Global Oncology, the US and Global HIV business of BMS and Genentech. We also provided promotion, training, market research, KOL research and mapping to oncology and hematology companies such as ImClone, Takeda, Millennium, Amgen, Novartis, Bayer, Poniard, and others. Among my greatest successes was developing and implementing the HER2 awareness pre-launch programs for 18 months until FDA approval of Herceptin. This consisted of various monographs and journal advertisements that were used to “create awareness” of the poor patient prognosis and clinical problems associated with HER2-positive metastatic breast cancer. We never mentioned the drug or molecule that became Herceptin. Because of our success Genentech hired us as agency of record to launch Herceptin, which we did quite successfully. Another great success was for Lilly. I convinced Dr. Johnson, the ECOG Lung Committee Chair, to replace Camptosar with Gemzar in the landmark four-arm ECOG 1594 clinical trial which catapulted Gemzar to immediate success in NSCLC.The reason that I sold my business in 2001 was because Lilly US Oncology fired their agency of record and offered the entire US agency business to me. That prompted an offer to buy my company from the agency that Lilly fired. I accepted.
  • Carrington Laboratories, Inc.
    Chief Operating Officer (Coo) & Executive Vice President (Evp)
    Carrington Laboratories, Inc. 1992 - 1994
    Irving, Tx
    Carrington Laboratories is a publicly-held company with its headquarters in Irving, TX. Its mission is to develop and commercialize medicinal products derived from the Aloe Vera plant. The marketed products were a line of wound care products. I reported to the President and CEO. In short, my 28 months in this position provided me with invaluable, senior line-management experience.Responsibilities, Successes & Learning More Management Skills• When I started with Carrington, annual sales were approximately $16 million and declining. When I resigned after 28 months, I had increased annual sales to nearly $22 million.• Managed a total of nine executives in marketing, marketing research, and business development, a field sales force of eighty-six representatives, and 5 field sales managers.• Worked closely with the VPs of R&D, Clinical and Medical Affairs, Regulatory Affairs, and several external clinical consultants to help to further develop the line of acemannan-based wound care products and, to assist in the early clinical development of acemannan as an anti-cancer agent.• Initial and main responsibility pf my position was to reverse the several years of declining wound care product sales and create annual business growth of at least 20% within two years. • Analyzed the quarterly sales results, earnings, and working with the Chief Financial Officer, I prepared the company’s financial statements, and provided the forward sales and business development guidance for the CEO and President to deliver this information every quarter as required of publicly-traded companies. • After being employed for 28 months I exercised my option to leave the company. I was recruited and officially offered the position of Sr. Vice President of Global Oncology Marketing, Sales, and Business Development at Johnson and Johnson (J&J) by the International President of J&J Pharmaceuticals. I declined the J&J offer and instead I started my own company in Dallas, TX.
  • Bristol-Myers Squibb
    Sr. Director, Marketing & Business Development, Latin America
    Bristol-Myers Squibb 1989 - 1992
    Mexico City, Mexico
    My major responsibilities were: 1) Ensure that each Bristol Myers Squibb (BMS) Latin American country general manager implemented the President of BMS Latin America’s core business and marketing strategies for the entire line of BMS prescription and OTC products. 2) Provide my prior successful US and international BMS and Eli Lilly marketing and business development experience to assist to all BMS Latin American country general managers and their senior executives, as needed, to increase sales. 3) Train and assist all BMS country general managers and their senior executives to help build and grow their oncology businesses. 4) Arrange oncology symposia in BMS Latin American countries by establishing rapport with Latin American oncology KOLs and by bringing US oncology KOLs to as many BMS Latin American markets as possible. I reported directly to the President of BMS Latin America, Sr. Don Emilio Gonzalez. I traveled throughout Central and South America for 3 weeks every 6 weeks to meet with the country general managers to train them on the core marketing strategies and tactics developed with the President of BMS Latin America and with cooperation from the US oncology marketing executives.The President of BMS Latin America hired me as his Executive Director because he knew of my good reputation helping many of his countries increase sales of oncology products during my first job at Bristol-Myers (1982-1985) as the first Global Oncology Product Manager, when I traveled occasionally to a few of his Latin American countries.I left BMS because of the heavy travel schedule of being on the road away from my wife for three consecutive weeks, every six weeks became a major strain on my marriage. And I received an official offer to become the Vice President of the US and Global Oncology business from the President of Johnson & Johnson (J&J) who flew to Mexico to personally offer me the job. Unfortunately my wife did not want to live in New Jersey, I declined the offer.
    View
  • Bristol-Myers Squibb
    Director, Global Anti-Infectives Business Development And Marketing, Bristol-Myers Squibb
    Bristol-Myers Squibb 1988 - 1989
    Princeton, Nj
    Responsible for commercial support of all anti-infectives and anti-fungals. I reported to the Executive Director who hired me.My main responsibility was as the sole business (marketing) member of a multi-disciplinary team including infectious disease physicians, pharmacologists, formulation experts, regulatory affairs executives, and other internal and external ad hoc members as needed, including Dr. Gabriel Lopez-Berestein an external academic KOL, to help with our team’s efforts to commercialize the promising oral liposomal anti-fungal, liposomal amphotericin B. Our liposomal oral anti-fungal product was in several early Phase II clinical trials for several different fungal infections and showed various levels of efficacy as an anti-fungal therapy with much lowered Amphotericin B side effects. It was hoped that our oral liposomal product would be able to show comparable efficacy to intravenous Amphotericin B for treating the mostly serious and sometimes life-threatening fungal infections but with significantly lower side effects. Previous lipid formulations that under development with oral Amphotericin B had very poor absorption. It was hoped that delivering Amphotericin B encapsulated in our proprietary liposome would improve the oral absorption while minimizing toxicity.My secondary responsibility was to investigate other infectious disease opportunities for our Amphotericin B, including, non-anti-fungal infections where a strong but more tolerable Amphotericin B would have a therapeutic niche.Our multi-disciplinary team next began evaluation of oral liposomal Amphotericin B, also being evaluated for “traveler’s diarrhea.” I found published research data that showed that one dose of ciprofloxacin was 99% percent effective treating traveler’s diarrhea. When I presented this data to our team, the decision made by senior management to discontinue all research on our liposomal Amphotericin B. I was then offered and accepted a position at BMS Latin America.
    View
  • Bristol-Myers Squibb
    Sr. Product Manager, Us Oncology, Bristol-Myers
    Bristol-Myers Squibb 1985 - 1988
    Syracuse, Ny & Evansville, In
    I was the first Sr. Product Manager of the newly formed Bristol-Myers US Oncology Division (1985). I was offered the position by the new US Oncology Director of Marketing, Tom Jordan, who knew about my work for two reasons: 1) because he worked at Mead Johnson In Evansville, IN, a Division of the parent Bristol-Myers Company which had a hormone treatment for breast cancer, he attended occasional joint oncology meetings between Mead Johnson and Bristol-Myers in New York where he met me and, 2) because he and my boss in New York boss, plus the Medical Director in New York had previously worked together at Adria Laboratories while they worked together at Adria Laboratories. They all spoke highly of me to Tom.I accepted the job for three reasons: 1) it was a line position with budgeting responsibilities, 2) it was an opportunity to work for a very bright and very experienced boss with a great reputation within our company and also among the oncology KOLs; everyone knew that Tom had great knowledge of oncology and experience, and, 3) After I could quickly demonstrate my skills and marketing abilities, Tom promised me considerable freedom to do my job. I was responsible for marketing the most important anti-cancer products of Bristol-Myers in the US: Platinol & Vepesid. I also managed two other anti-cancer products, including Mutamycin & Blenoxane.How I succeeded: I leveraged my increasing number of relationships with as many academic lung cancer KOLs, several of whom I had already established solid working relationships from my previous job at Bristol-Myers International. Perhaps my greatest success was that I planned and conducted a major symposium for Platinol & VePesid for lung cancer. I chose Dr. Einhorn who cured testicular cancer with a 5-drug regimen that included Platinol & VePesid. I chose the expert KOL lung cancer faculty and published the symposium proceedings. That firmly established Platinol & VePesid as the SCLC standard of care.
    View
  • Bristol-Myers Squibb
    Product Manager, Bristol-Myers Global Oncology
    Bristol-Myers Squibb 1982 - 1985
    New York, Ny
    I was the first Product Manager of the newly formed Bristol-Myers Oncology unit (1983) within the Bristol-Myers International Division (BMCID). I reported to the Director of Oncology Marketing.One of my earliest objectives that I met and exceeded as the sole Bristol-Myers oncology Product Manager, was that I established strong rapport with our European and Canadian oncology marketing managers and created the first unified marketing team of our International Division. I exceeded the initial objectives in my position by conducting three quarterly meetings each year in Switzerland (to show strong support for our European and Canadian affiliates) and one meeting annually in New York City at the Bristol-Myers headquarters, where I led the international country managers to jointly adopt core promotional programs, paid for by my Bristol-Myers Oncology budget in New York. Among my many other successes were the following: I launched high-dose Platinol in 1983 and VePesid in 1984 in major European countries and Canada. I developed rapport with the several US academic medical oncology KOLs for ovarian cancer, especially those who supported the use of high-dose and outpatient administration of cisplatin. I developed rapport with several North American academic medical oncology KOLs who supported the use of VePesid for small cell lung cancer, including three US KOLs. I Increased Platinol sales by more than 50% by bringing the aforementioned US KOLs to speak about high-dose and outpatient Platinol at numerous Bristol-Myers-sponsored symposia in each European country and Canada. I started launching VePesid and Paraplatin in Europe and Canada in early 1984. I conducted a three-week country by country road show in all major European markets plus Canada to introduce strategies and tactics to promote the new anti-aerosolization vials for using liquid cisplatin. This was eventually replaced by liquid Platinol that I launched near the end of my tenure in this position.
    View
  • Eli Lilly & Company
    Associate Product Manager, Us Anti-Infectives, Ceclor
    Eli Lilly & Company 1982 - 1983
    Indianapolis, In
    I was given the prestigious marketing position to work on Ceclor which was the most important new product at Eli Lilly at that time. I reported to the Ceclor Product Manager as his only Associate Product Manager only a few months after US launch.How I succeeded: I supported the US Ceclor Manager in a variety of ways, including traveling to meet with and establish rapport with pediatric, infectious disease key opinion leader physicians (KOLs).I assisted the Product Manager in any way requested to help increase Ceclor sales.I prepared drafts of regular Ceclor clinical updates and competitive communications to the sales force for both myself, and my boss, the Product Manager. I developed strong working relationships with the US pediatric, infectious disease key opinion leader physicians (KOLs) to help increase Ceclor sales.I wrote monthly new promotional tactics and mailed them to the Eli Lilly sales force to support Ceclor sales growth.I met monthly with our advertising agency in New York to develop promotional materials for the national sales force, and Ceclor journal advertisements.I performed analysis of our competition and reviewed internally-created market research for use in developing promotional strategies for Ceclor.I met regularly with our Ceclor Clinical team to receive and analyze updates that I used to help develop Ceclor marketing and sales strategies and tactics.I was the fortunate recipient of numerous, ongoing executive development programs and courses such as letter writing, how to develop presentations, time management skills, leadership skills and other executive skills.Practically everyone in marketing positions at Eli Lilly were being recruited by other pharmaceutical companies because being an Eli Lilly executive at any level meant that you were highly skilled and highly trained and considered a valuable addition to most other pharmaceutical companies. I accepted the first Product Manager's position at Bristol-Myers Oncology in NYC.
  • Eli Lilly & Company
    Associate Product Manager, Global Anti-Infectives, Ceclor
    Eli Lilly & Company 1980 - 1981
    Indianapolis, In
    Was given the opportunity to work on Ceclor in ex-USA markets. Ceclor was initially launched in Europe and was the most important new oral product at Eli Lilly at that time. I reported to the Global Ceclor Product Manager as his only Associate Product Manager.How I Succeeded:I supported the Global Ceclor Manager to help increase Ceclor sales ex-USA. mainly in Europe and Canada.I helped prepare all communications to Europe and Canada for post-launch Ceclor marketing activities. Prepared drafts of regular Ceclor clinical updates and competitive communications to the European and Canadian markets.
  • Eli Lilly & Company
    Sales Representative, Chicago
    Eli Lilly & Company 1976 - 1980
    Chicago, Ill
    Sold antibiotics, a new non-steroidal anti-inflammatory analgesic, a line of topical steroids, and several other products prescribed by Family Practitioners, Internists, Rheumatologists, Pediatricians, Orthopedic Surgeons, and Dermatologists.How I Succeeded:I became the number one salesman in the Chicago District after one year.I maintained my position among the top 10% sales representatives in the entire USA Dista Products national sales force as follows:I established working relationships with numerous pharmacists throughout my territory enabling me to look through their pharmacy’s prescription files in order to identify high-prescribing physicians and identify who was using or not using my products.I worked harder than anyone in my Chicago District and, harder than my competitors. While most sales representatives worked less than 8 hours per day, I worked 10+ hours almost every day, and an unprecedented occasional Saturday.I developed highly successful strategies to overcome obstacles such as “snow days” so that I could see doctors with policies that didn’t see sales representatives.I worked in the early mornings to meet doctors in hospital parking lots as they were arriving at their hospitals. I was the top vitamin deal sales representative in our District during our semi-annual vitamin sales contest for 1979 and 1980.After two years I was voted by my Chicago District sales representative peers as best sales representative, and I was given two plaques custom made by my fellow sales representatives as an unofficial recognition of leadership in my District.Because after 12 months, I reached and maintained a position among the top 10% of all Lilly sales representatives in the US, Lilly paid for my entire MBA Program at DePaul University which I attended three nights each week for three hours per day. I worked full-time as a sales representative during the day and attended night MBA classes "all year round" until I completed my MBA program.

Stephen G. Madison, Bscpharm, Rph, Mba Skills

Oncology Pharmaceutical Industry Product Launch Medical Education Biotechnology Cancer Healthcare Hematology Pharmaceutics Dermatology Pharmaceutical Sales Hospital Sales Medicine Life Sciences Clinical Trials Market Access Diabetes Clinical Development Marketing Strategy Neurology Clinical Research Infectious Diseases Product Development Strategic Planning Immunology Market Research Cardiology Product Launches Pharmaceuticals Business Strategy Market Planning Marketing Management Urology New Business Development Competitive Analysis Product Management

Stephen G. Madison, Bscpharm, Rph, Mba Education Details

Frequently Asked Questions about Stephen G. Madison, Bscpharm, Rph, Mba

What company does Stephen G. Madison, Bscpharm, Rph, Mba work for?

Stephen G. Madison, Bscpharm, Rph, Mba works for Steve Madison Cancer Consulting

What is Stephen G. Madison, Bscpharm, Rph, Mba's role at the current company?

Stephen G. Madison, Bscpharm, Rph, Mba's current role is President and CEO.

What is Stephen G. Madison, Bscpharm, Rph, Mba's email address?

Stephen G. Madison, Bscpharm, Rph, Mba's email address is bs****@****bms.com

What is Stephen G. Madison, Bscpharm, Rph, Mba's direct phone number?

Stephen G. Madison, Bscpharm, Rph, Mba's direct phone number is +121426*****

What schools did Stephen G. Madison, Bscpharm, Rph, Mba attend?

Stephen G. Madison, Bscpharm, Rph, Mba attended University Of Illinois Chicago, Depaul University, University Of Illinois Chicago, Depaul University.

What skills is Stephen G. Madison, Bscpharm, Rph, Mba known for?

Stephen G. Madison, Bscpharm, Rph, Mba has skills like Oncology, Pharmaceutical Industry, Product Launch, Medical Education, Biotechnology, Cancer, Healthcare, Hematology, Pharmaceutics, Dermatology, Pharmaceutical Sales, Hospital Sales.

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant

Download 750 million emails and 100 million phone numbers

Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.